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The JMH blood group system consists of six high-prevalence 
antigens. These antigens are located on the Sema7A protein. The 
molecular basis of the JMH1– phenotype is not known; however, 
single nucleotide changes in the SEMA7A gene on chromosome 
15 account for the other JMH antigens. JMH1, commonly known 
as JMH, is most notable because transient depression of the 
antigen occurs and anti-JMH may develop. These antibodies are 
most commonly observed and are not significant in transfusion. 
Antibodies developed in the rare JMH variant types may cause 
reduced red cell survival. This review provides a general overview 
of the JMH blood group system, including the serologic and 
molecular characteristics as well as proposed functions of the 
Sema7A protein. Immunohematology 2014;30:18–23.
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Introduction
The JMH blood group system has the distinction of being 
the blood group with the most “nicknames.” The “over 60 
group,” “John Milton Hagen group,” “The Boys,” “The Cat,” 
and the “Old Boys’ Club” have all been used in reference to the 
antibody and antibody makers.1 The earliest accounts in the 
1970s were of antibody reactivity, followed by description of 
the protein carrying the antigens (semaphorin 7A or CD108), 
and finally with identification of the gene SEMA7A, JMH 
earned its rightful status of blood group system 026 in 2001.
Antibodies to JMH antigens are encountered infrequently 
but have unique characteristics landing them their nicknames. 
The “over 60 group,” “The Boys,” and the “Old Boys’ Club” 
all are derived from early observations that many of the 
antibodies were found in older gentleman. Older has been 
defined as >50 or 60 years of age. Like Issitt,2 I concur that 
old is recognized as mature, wiser, and experienced patients. 
Not to leave the ladies out of describing these antibodies, the 
nickname “The Cat” came from one of the first women who 
produced anti-JMH. She is said to have claimed the anti-JMH 
occurred when her cat died (Marilyn Moulds, March 2012, 
personal communication).
The significance of antibodies to JMH antigens in trans-
fusion and pregnancy are minimal and will be discussed.
History
In March 1973, a male patient in his 60s was to have 
elective orthopedic surgery. He had no history of transfusions. 
A weakly reactive antibody detected by the indirect antiglobulin 
test (IAT) was not reactive with papain- or ficin-pretreated 
cells. No compatible blood was available, and units collected for 
autologous transfusions were never given. It was reported as 
an “antibody to high-incidence unknown factor,” and samples 
were sent to other laboratories for investigation. This result led 
to a group of antibodies being collected in the 1970s that were 
compatible with this individual’s red blood cells (RBCs) and 
had similar reactivity. They were first mentioned in print by 
Issitt in 1975 as the John Milton Hagen group of antibodies, 
as he termed them “belonging to a group of high-incidence 
antigens of which little is known about.” His remarks were 
based on personal communication with John J. Moulds.3 The 
first antibody was reported to be recognized in 1970 per Sabo 
et al.,4 who further characterized 49 sera with similar reactivity 
and proposed giving this antibody the symbol JMH, naming it 
after one of the original antibody makers, and adding it to the 
list of high-titer, low-avidity antibodies. These antibodies were 
of high titer and weakly reactive in saline IAT with all RBCs 
tested, except autologous cells and other JMH– RBCs.
Dedication
This review is dedicated to John J. Moulds, MT(ASCP)SBB, as he was instrumental in bringing a group of antibodies with 
interesting serologic characteristics to the blood group it is today. In the classic “Moulds” way throughout his life and career, he 
always challenged young SBBs and laboratory scientists to question unusual serologic results. He would say, “They are telling 
you something.” The JMH blood group system is a testament to his beliefs. He is coauthor on many papers in this review. John 
called me to provide additional information he found important to the JMH story. I am honored and privileged to have known 
John, to have been challenged by John, and to write this review as a tribute to his work.
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In the 1980s, work was done to further define the serologic 
characteristics of anti-JMH and its reactivity with chemically 
modified RBCs, namely those treated with proteases, 
sulfhydryl-reducing agents, and neuraminidase. In addition, 
attempts were made to predict the clinical significance of anti-
JMH in transfusion using chromium-51 RBC survival studies 
and subclassing.5 In 1982, a monoclonal antibody named H8 
was described with JMH specificity.6,7 This antibody was 
important to further work in characterizing the JMH protein. 
In addition, J.J. Moulds reported evidence that there was 
heterogeneity in reactivity of different anti-JMH.8
Telen et al.9 reported in 1990 that several high-incidence 
antigens including the JMH antigen were absent on RBCs 
of individuals with paroxysmal nocturnal hemoglobinuria 
(PNH). PNHIII RBCs were previously shown to lack 
glycosylphosphatidylinositol (GPI)-linked proteins, and 
when these RBCs were tested with human anti-JMH and 
monoclonal H8, no reactivity was seen. This result suggested 
that JMH must reside on a GPI-linked membrane protein. 
Immunoprecipitation and immunoblotting experiments on 
human anti-JMH and H8 showed JMH resides on a 76-kD 
phosphatidylinositol-linked protein.10 Finally, the location of 
JMH was determined to be on the CDw108 glycoprotein, now 
known as semaphorin 7A.11
Having knowledge of the location of JMH, the cDNA clone 
containing the CDw108 gene was identified in 1999.12 The 
gene resides on the middle of the long arm of chromosome 15. 
This CDw108 gene is now known as SEMA7A and is located 
on 15q23–24. The genetic information earned JMH its own 
blood group system in 2001 named John Milton Hagen, 026, 
and its symbol JMH.13 JMH1 is the antigen detected by most 
individuals making anti-JMH. Four additional variant JMH 
genotypes were added in 2007.14 JMHQ was proposed in 2011, 
reported in four Native Americans whose RBCs were JMH1–, 
with most examples of anti-JMH, and officially recognized 
later that year.15
Today, there are six recognized antigens in the system 
summarized in Table 1.16,17 Each antigen is defined by 
antibodies nonreactive with JMH1– RBCs.
Nomenclature
Nomenclature resulting from serologic observations and 
biologic and molecular studies has remained very simple for 
the blood group with so many nicknames. The antigen name 
commonly known by serologists remains JMH and is officially 
recognized by the International Society for Blood Transfusion 
(ISBT) as JMH1. Confirmed JMH variants are sequentially 
numbered for example, JMH2 and named with the first letter 
from the antibody maker’s first name (JMHK) following JMH.
JMH Glycoprotein
Antigens in the JMH blood group system are carried 
on the protein semaphorin 7A, also known as Sema7A and 
CD108. Mature Sema7A consists of 525 amino acids. Changes 
in amino acids 207 and 460/461 were noted by Seltsam in 
JMH-variant individuals. A three-dimensional model of the 
crystal structure of Sema7A was proposed (Fig. 1A and B).14 
Position 207 is located at the top face of the sema domain, 
whereas positions 460 and 461 are on the bottom.
As mentioned previously, Sema7A protein binds to the cell 
membrane by a GPI linkage. Not only is it present on RBCs, 
it is present on lymphoid and myeloid cells as well as bone 
cells, neurons of the brain and spinal cord, thymus, spleen, 
gut, kidney, heart, and placenta. Sema7A is found primarily in 
activated T cells and thymocytes.18
Table 1. The John Milton Hagen blood group system
Number Name Prevalence Molecular basis of antigen-negative phenotype
JMH1 JMH High Not known
JMH2 JMHK High 619C>T R207W
JMH3 JMHL High 620G>A R207Q
JMH4 JMHG High 1379G>A R460H
JMH5 JMHM High 1381C>T R461C
JMH6 JMHQ High 1040G>T R347L
Fig. 1 Three-dimensional model of Sema7A (reprinted with 
permission from AABB). Image courtesy of A. Setsam. (A) A cartoon 
of the sema domain when looking down on the protein. The numbers 
represent propellers. (B) A side view of the sema domain. The 
polymorphic amino acid positions 207, 460, and 461 are circled.
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Numerous roles for Sema7A have been proposed. It is 
clear it is involved in cytokine expression, chemotaxis, and 
axon guidance signaling.19 In effector T cells, it likely promotes 
macrophage recruitment to sites of inflammation.18,20,21 A 
recent report shows the Sema7A_R461C variant (JMH5) 
causes different T-cell responses than the wild-type Sema7A.22 
It is able to strongly activate CD4+ T cells and change their 
phenotype to a more cytotoxic one, and evidence is provided 
that Sema7A_R461C delivers costimulatory signals to T cells, 
causing them to increase their release of cytokines such as 
interleukin (IL)-1β, IL-6, and IL-8.
Sema7A has also been reported to be an important 
regulator of tissue remodeling. In genetic studies in Korean 
women with decreased bone mineral density, mutations in 
SEMA7A were found.23 Sema7A also contributes to regulation 
of tissue fibrosis and remodeling.24
The exact function of semaphorin 7A on RBCs is not 
known, but it likely plays a role in cell migration as an adhesion 
molecule.25 It may also play a role as a receptor for Plasmodium 
falciparum. It was identified as a receptor for the P. falciparum 
merozoite-specific thrombospondin-related anonymous pro- 
tein (TRAP) homolog in laboratory experiments using 
recombinant protein.26
JMH Antigen Characteristics
JMH1 is the primary antigen in the system and is 
present in greater than 99 percent of all individuals. The 
JMH1-negative phenotype occurs as either inherited or more 
commonly acquired depression of the antigen. The JMH 
antigen is most commonly depressed in a transient manner. 
In these individuals, the antigen is often below the level of 
detection by standard serologic methods and they make anti-
JMH. This result likely explains the serologic observation 
of a positive direct antiglobulin test (DAT) seen in many 
individuals with anti-JMH. There has been no genetic change 
identified in the SEMA7A gene of these individuals.14 The 
transient phenomenon may be triggered by an autoimmune 
process like that seen in other blood group systems.
There is only one family described with the inherited 
negative phenotype identified when randomly screening 
donors. In this family, it was shown that three generations of 
individuals possessed JMH– RBCs, consistent with autosomal 
dominant inheritance.27 None had made anti-JMH, and all 
had a negative DAT.
Rare JMH variants have been described with reduced or 
variable expression of JMH antigen (Table 1).14 All possess an 
antibody that is not reactive with JMH1– RBCs. However, 
variable reactivity is seen when the specificity of each antibody 
is cross-tested with other JMH variants (Table 2).28 JMH 
antigens are destroyed by various chemicals, as shown in 
Table 3, characteristic of other blood group antigens on GPI-
linked proteins. PNHIII cells can be used as a source of JMH– 
RBCs as well.29
The SEMA7A Gene: Genetics and Inheritance
SEMA7A is located on 15q22.3-q23, the middle of the 
long arm of chromosome 15 (GenBank accession number 
BC101647), and is organized in 14 exons. To date, no nucleotide 
changes have been identified in individuals with JMH– RBCs. 
JMH variants result from changes in nucleotides in exons 6 
and 11 (Table 1).
Rare individuals who lack Sema7A on their RBCs possess 
Sema7A on other cells. Given the information provided from 
molecular analysis performed to date, this is likely because of 
a posttranscriptional mechanism.14
JMH Antibodies
Anti-JMH is found most often as the acquired form and 
as such can be found in individuals with no prior transfusions 
Table 2. Anti-JMH and JMH-related antibodies tested with JMH– 
and variant JMH red blood cells
Anti-
Phenotype JMH1 JMH2 JMH3 JMH4 JMH5 JMH6
JMH:-1 0 0 0 0 0 0
JMH:-2 + 0 0 + + NA
JMH:-3 + 0 0 + + NA
JMH:-4 + + + 0 + NA
JMH:-5 + + + 0 0 NA
JMH:-6 + NA NA NA NA NA
NA = not available.
Adapted from Daniels.27
Table 3. Characteristics of antigens in the John Milton Hagen 
blood group system
Sensitive to ficin or papain treatment
Sensitive to trypsin and alpha chymotrypsin treatment
Sensitive to 2-aminoethyl-isothiouronium bromide and 200 mmol/L/ 
50 mmol/L dithiothreitol treatment
Sensitive to sialidase treatment
Resistant to chloroquine treatment
Absent from paroxysmal nocturnal hemoglobinuria-III red blood cells
Weakly expressed on cord cells
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or pregnancies. JMH antibodies are weakly reactive in a saline 
IAT. All RBCs tested will show positive reactivity. Using a 
scale of 0 to 4+, weak macroscopic to 2+ reactivity is common. 
More consistent, stronger positive reactivity may be seen when 
testing donor RBCs using column agglutination or solid-phase 
methods. All anti-JMH, whether found in JMH– or JMH-
variant individuals, are negative with JMH:-1 RBCs.
Some JMH antibodies made by JMH-variant individuals 
are nonreactive with other JMH variants (Table 2). These 
individuals will not have a positive DAT or positive autocontrol, 
as seen in the majority of individuals with depressed JMH 
antigen.
As mentioned previously, PNHIII cells may also be used 
as a source of JMH– selected cells, as they lack all GPI-linked 
proteins.29 The characteristic finding is the autocontrol being 
weakly positive and weaker than the antibody reactivity with 
panel cells. The DAT is also weakly positive with polyspecific 
anti-human globulin (AHG) and anti-IgG. Interestingly, the 
eluate is usually negative, but there are rare reports of anti-
JMH in the eluate.30
JMH antibodies are predominantly IgG4 subclass.31–33 A 
rare example of a presumed significant IgG3 anti-JMH has 
also been described.34 The IgG subclass is important to keep in 
mind when identifying anti-JMH. Some AHG reagents on the 
market lack anti-IgG4. If using this AHG reagent, no reactivity 
will be observed in any IAT regardless of methodology. 
Additional characteristics of JMH antibodies are summarized 
in Table 4.
Soluble recombinant JMH proteins have been produced 
that will inhibit anti-JMH.14 These soluble proteins are not 
available commercially at this time. However, they could be 
useful in confirming anti-JMH specificity as well as in ruling 
out underlying alloantibodies.
A novel approach to detecting anti-JMH is through the 
use of particles coated with purified, recombinant Sema7A 
protein in a gel card format.35 If recombinant proteins could 
be manufactured for all common blood group antigens, they 
could replace the need for donor RBCs. This is an ongoing area 
of investigation.
Clinical Importance
The acquired type JMH-negative individuals producing 
anti-JMH have not been associated with adverse transfusion 
episodes.36 It is routine transfusion practice today to give 
crossmatch-incompatible blood to these patients.
Rare, inherited-variant JMH-negative individuals who 
have made anti-JMH have been associated with decreased 
RBC survival.37 One additional patient, later confirmed to be 
a JMH variant by molecular analysis, was also reported to 
experience an acute hemolytic transfusion reaction.14,38
Another report of an IgG3 antibody and a positive 
monocyte monolayer assay suggested the antibody was 
significant, but the patient did not require transfusion.34 
Molecular studies were not performed to determine whether 
this was a JMH-variant individual.
Very little is known about anti-JMH in pregnancy 
because most individuals with anti-JMH are older women or 
men. In addition, JMH is very weakly expressed on cord cells. 
One example of a 32-year-old pregnant woman with a JMH-
weak phenotype and anti-JMH gave birth to a baby with no 
evidence of hemolytic disease of the fetus and newborn.14
Conclusions
The John Milton Hagen blood group system is fairly 
straightforward, but it took more than 30 years to organize 
serologic observations of the original group of antibody 
makers to determine its biochemistry and molecular genetics, 
and to it finally being named its own blood group system, 026. 
Investigation of this system, led by the work of John J. Moulds, 
taught us the value of sharing rare RBCs and fluids to further 
identify unusual antibodies and to fully evaluate antibody 
identification results that do not make sense. To build on his 
legacy, readers are encouraged to continue to question unusual 
serologic results and use the molecular tools available to find 
new, interesting, and exciting findings to add to this system 
and other blood group systems, or perhaps to discover a new 
system.
Table 4. Characteristics of antibodies to John Milton Hagen 
antigens
Immunoglobulin G (IgG)
Usually IgG4-negative with anti-human globulin lacking IgG4 anti-IgG
Usually weakly reactive (<2+) in test tube methods
Nonreactive with papain or ficin-treated RBCs
Nonreactive with trypsin or alpha chymotrypsin
Reactive with chloroquine-treated RBCs
Nonreactive with 200 mmol/L/50 mmol/L dithiothreitol treatment or 
2-aminoethyl-isothiouronium bromide-treated RBCs
Not inhibited with pooled normal serum
Do not bind complement
Antibodies may be transient (detectable when individuals RBCs have 
reduced expression of antigen)
Do not cause hemolytic disease of the fetus and newborn
RBC = red blood cell.
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